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ABSTRACT 
Immunotherapy belongs to the group of targeted therapies; it is based on natural immune mechanisms 
which axis can be promoted or blocked at appropriate points. Breast cancer is the world’s most common 
cancer among women and in March 2019 the FDA approved the first immunopharmaceutical Atezolizum-
ab, for the treatment of breast cancer. So far, the only registered marker for classification for checkpoint 
inhibitor therapy has been the presence of PD-L1 receptor expression in tumour cells.
A comprehensive search of the literature to elucidate the correlation between PD-1/PD-L1 single nucleo-
tide polymorphism (SNP) and cancer, especially breast cancer or other diseases susceptibility and PD-1/
PD-L1 expression. 
Seven susceptibility loci was considered: rs41386349, rs7421861, rs36084323, rs11568821, rs2227981, 
rs10204525, rs2227982. Three of them may be taken into account as potentially helpful in breast cancer 
patient treatment tailoring: rs36084323, rs2227981, rs2227982. 
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Liquid biopsy (LB) is the most superior diagnostic 
method for the determination of the tumour signature 
in blood [1]. 
Breast cancer is the most common female cancer 
worldwide. Only in 2018, it reached the top rate among 
25 cancers for 40 countries in Europe (523,000 cases, 
within 3.91 million new cases of cancer per year in both 
genders) [2]. In simplified words, the prognosis de-
pends on the tumour type (lumina, basal-like, triple-neg-
ative) and its stage (histological grade, axillary lymph 
node involvement and distant metastasis) at the time of 
diagnosis. Despite low immunogenicity in breast cancer 
[3], there is a rising interest in anti-programmed dead 
receptor 1 and programmed dead ligand 1(anti-PD1/an-
ti-PD-L1) treatment in a special subset of triple-negative 
breast cancer (TNBC) and human epidermal growth 
factor receptor 2 positive (HER-2 positive) [4–6]. In 
March 2019, FDA approved Atezolimumab (Tecentriq) 
for adult patients with unresectable, locally advanced 
or metastatic triple-negative breast cancer (TNBC) the 
tumours of which express PD-L1 as determined by an 
FDA-approved test [7].
PD-1 firstly identified by Ishida in 1992 [8] is a trans-
membrane glycoprotein located in tumour cells, cyto-
toxic T-lymphocytes, natural killer (NK), B-lymphocytes, 
monocytes and other tissues infiltrating lymphocytes 
(TILs) [9]. PD-1 receptors linked with their ligands 
PD-L1 identified in 1999 [10] on an antigen presenting 
cell (APC) inhibit antitumour activity. PD-1/ PD-L1 axis 
block activation of cytotoxic T-cell. This blockade plays 
a critical role in tumour resistance mechanisms. The 
suspension of PD-1/PD-L1 axis can restore T-cell and 
promote immunity against tumour. Antitumour effect 
exerted via immunocheckpoint inhibitors (Atezolizumab, 
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Avelumab, Nivolumab, Pembrolizumab) is based on 
the promotion of a cell-mediated immune response. 
To date, for the purpose of pretreatment qualification, 
FDA-approved only the PD-L1 expression level, as 
determined by an IHC based on the VENTANA assai 
[7] for a primary or metastatic tissue source. It is still 
unclear if PD-1(PDCD1)/PD-L1(Pdcd1l2) gene single 
nucleotide polymorphism (SNP) could be a predictor 
for immunocheckpoint inhibition treatment, especially 
in the context of breast cancer risk and prognosis [11, 
12]. The frequencies of rs36084323 GG genotype and 
rs2227981 CT genotype can affect the susceptibility of 
breast cancer [12]. The human gene encoding PD-1 is 
located on 2q37.3 [12]. 
Programmed death-1 (costimulatory 
molecule, PD-1, CD279) gene 
polymorphism/ PDCD1 (coding for 
programmed cell death-1)
Loci of PD-1 gene might be a potential biomarker 
for predicting susceptibility to therapeutic markers 
for cancer treatment. However, the identification 
of biomarkers able to predict a clinical benefit of 
PD-1/PD-L1 inhibitors  seems to be a challenge. To 
apply liquid biopsy into minimal invasive stratification, 
single nucleotide polymorphism (SNP) should be des-
ignated. Seven susceptibility loci for immunotherapy 
effect in breast cancer patients can be considered: 
rs41386349, PDCD1 (rs7421861), PD-1.1 (rs36084323), 
PDCD-1.3 (rs11568821), PDCD-1.5 (rs2227981), PD-
CD-1.6(rs10204525), PDCD-1.9 (rs2227982). Previous 
studies have discussed methods and combined bio-
markers from different points of view: tumour mutation 
and neoantigens burden as well as some oncogene 
mutations like EGFR, ALK, KRAS and STK11 [13].
However, PD-L1 expression measured using the 
IHC is the only FDA-approved test. Lower PD-1 ex-
pression has been found to be associated with G of 
rs10204525 [14]. 
Certain single nucleotide 
polymorphisms (SNPs) in genes such 
as PDCD1 (coding for programmed 
cell death)
Rs41386349, this SNP was previously considered 
as a hot point for Grave’s disease and Addison’s 
disease [15], rheumatoid arthritis (RA) [16], Kawa-
saki disease [17], multiple myeloma [18] and variant 
A for  rs41386349  affects susceptibility of chronic 
HBV [19]. Whereas, only PD-L1 rs1411262C/T gene 
polymorphism in the case of Grave’s disease and 
Addison’s disease [15], increased rheumatoid factor 
seropositivity [16] and a higher probability of Kawasaki 
disease [17] was discovered. The multiple myeloma 
occurs more often with a PDCD1 GCC/GCC haplotype 
(rs36084323/rs41386349/rs2227982) variant [18]. 
PDCD1  (rs7421861) has been studied in case of 
esophageal cancer [20] and chronic HBV infection, its 
oncogenicity [19] as well as RA [16]. PDCD1 gene poly-
morphisms influence the severity of a disease and are 
associated with distant metastasis, higher TNM stage, 
higher PD-1 gene and plasma levels in esophageal 
cancer patients and risk of esophageal cancer in general 
[20]. This gene variability may play a role in hepatocar-
cinogenesis caused by chronic HBV infection [19]. Tseng 
CC et al. have found higher expression of PDCD1 in RA 
compared to controls. However, PDCD1 gene polymor-
phisms were similar in this study [16]. 
PD-1.1 (rs36084323) has been considered in a case 
of breast cancer [21], epithelial ovarian cancer [22] 
esophageal cancer [20], NSCLC [23], overall cancer 
risk [24], RA [16] pregnancy losses [25] and aplastic 
anemia [26]. Therefore, significantly lower frequencies 
of PD-1.1 GG have been presented in women with 
breast cancer [21]. Rs36084323 polymorphism pre-
dicts epithelial ovarian cancer development [22]. No 
association with esophageal cancer metastasis [20], 
no differences in the distribution of the PD-1.1 alleles 
in NSCLC [23], no association between overall can-
cer risk have been obtained [24]. For autoimmune 
diseases, such as RA, rs36084323 decreased an 
inadequate response to conventional synthetic dis-
ease-modifying antirheumatic drugs [16]. Hayashi Y. 
et al. have evaluated the association of genetic variants 
of PD1 with recurrent pregnancy loss with significantly 
higher frequencies of rs36084323 in women with two 
or more pregnancy losses [25]. Polymorphism of PD-
1.1 has been rare in the case of patients with aplastic 
anaemia [26].
PDCD-1.3 (rs11568821) gene polymorphism has 
been considered to be related to an overall cancer 
risk [24, 27] and SLE [28]. Researchers have found 
a decreased overall cancer risk in case of PDCD-1.3, 
variant TC [24, 27]. PD1.3GG genotype and G allele 
have been significantly more frequent in SLE patients 
[28]. Prokunina et al. have found that this genetic 
variant would affect PD-1 mRNA level by changing 
the binding affinity of RUNX (a transcriptional factor 
of PD-1) [29]. 
PDCD-1.5 (rs2227981) variant TT has been associat-
ed with a decreased risk of cancer [24, 27]. CT genotype 
has been significantly lower in breast cancer women [21], 
whereas an increase in the risk of cervical [30], T-allele of 
rs2227981 gene polymorphism reduced risk of epithelial 
ovarian cancer [22], lung [31], gastric [32], colon [33], 
thyroid cancers [34] and CC variant was significantly 
more frequent in patients suffering from SLE [28]. 
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PDCD-1.6 (rs10204525) has been explored with 
respect to the associations between  PD-1.6  gene 
polymorphisms and esophageal cancer [20, 35], 
overall cancer risk [24], aplastic anemia [26], juvenile 
idiopathic arthritis [36] and HBV infection [37]. GG 
genotype of rs10204525 polymorphism has increased 
the risk of esophageal cancer in contrast to the more 
common AA genotype which was associated with 
distant metastasis and higher PD-1 gene and plasma 
levels [20, 35]. Even in some other work, there is no 
relation between this SNP and overall cancer risk [24]. 
Furthermore, some variants of rs10204525 have been 
linked to aplastic anaemia [26], while the CT variant was 
associated with juvenile idiopathic arthritis and linked 
to Anti-CCP antibodies, RF, and the CHAQ score [36]. 
Next, subjects carrying minor allele G had a significantly 
decreased risk of getting infected with HBV and were 
associated with lower PD-1 expression [14], variant AA of 
PD-1 rs10204525 was prone to higher PD-1 expressions 
in tumour tissues, peri-tumour tissues and cirrhotic tis-
sues [37]. GG genotype variant altered tumour necrosis 
factor-a (TNF-a) to increase levels in HBV patients [38]. 
PDCD-1.9 (rs2227982) has been evaluated in terms 
of breast cancer [39], ovarian cancer [40], ankylosing 
spondylitis [41], multiple myeloma [18] and chronic 
HBV infection and its oncogenity[19]. This polymor-
phism increases the probability and severity of the 
disease in case of ankylosing spondylitis and breast 
cancer [39, 41]. Simultaneously, the same reserchers 
have found that C > T variant reduces the risk of breast 
cancer [39] and raises the risk of ovarian cancer [40]. 
CC genotype variant was significantly correlated with 
a higher frequency of osteolysis [18]. This gene poly-
morphism may have a significant influence on hepato-
carcinogenesis [19]. However, CC of rs2227982 variant 
had a shielding role in HBV infection [14]. 
Conclusions 
In summary, there are no reports on PD-1 gene 
polymorphism and its association with immunotherapy 
favourable outcome susceptibility. Seven suscepti-
bility loci was considered: rs41386349, rs7421861, 
rs36084323, rs11568821, rs2227981, rs10204525, 
rs2227982. The important question for developing 
next-generation anti-PD-1/PD-L1 antibodies is wheth-
er the therapeutic effect can be predicted with SNP 
analysis using liquid biopsy. Nevertheless, three 
SNP may be taken into account in the breast cancer 
patient: rs36084323, rs2227981, rs2227982.
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